-
1 Comment
Daito Pharmaceutical Co.,Ltd is currently in a long term downtrend where the price is trading 7.1% below its 200 day moving average.
From a valuation standpoint, the stock is 98.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.1.
Daito Pharmaceutical Co.,Ltd's total revenue rose by 6.4% to $12B since the same quarter in the previous year.
Its net income has increased by 1.8% to $1B since the same quarter in the previous year.
Based on the above factors, Daito Pharmaceutical Co.,Ltd gets an overall score of 3/5.
| Sector | Healthcare |
|---|---|
| ISIN | JP3486150000 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | TSE |
| CurrencyCode | JPY |
| Beta | 0.23 |
|---|---|
| Market Cap | 31B |
| PE Ratio | 14.3 |
| Target Price | 1960 |
| Dividend Yield | 3.3% |
Daito Pharmaceutical Co.,Ltd. manufactures and sells pharmaceutical products worldwide. It offers generic drugs, active pharmaceutical ingredients, and over the counter drugs; and contract manufacturing services for formulations products, high-potent drugs, and packaging. The company was formerly known as Daito Corporation and changed its name to Daito Pharmaceutical Co.,Ltd. in 1992. Daito Pharmaceutical Co.,Ltd. was incorporated in 1942 and is headquartered in Toyama, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4577.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
